Team

Pradyut Shah is a senior investment partner at SAIGroup and oversees all investment and acquisition activity at the firm. He has led the acquisitions of multiple companies at SAIGroup, notably the acquisitions of Get Well, CancerLinQ, 1010data, NetReveal, Proceedix, ReTech Labs, Savigent, TeraRecon, Azima, Ayasdi, and MAI.

Pradyut was previously a Managing Director and founding member of Insignia Capital Group, a middle-market private equity firm where he served as a Director on the Boards of portfolio companies in the consumer sector. Prior to Insignia, he was a Vice President at Behrman Capital where he was significantly involved with a number of private equity investments from 2004 to 2011, including Athena Diagnostics, Brooks Equipment Company, Peacock Engineering Company, Pelican Products and WIL Research Laboratories. Prior to Behrman, Pradyut spent 3 years at Credit Suisse First Boston’s Technology Group.

He attended the Jerome Fisher Program in Management & Technology at the University of Pennsylvania, where he graduated summa cum laude with a B.S.E. in Computer Science from the School of Engineering and Applied Science and a B.S. in Economics with a major in Finance from the Wharton School of Business.

Eshwar Belani is an accomplished executive and a pioneer in the AI and technology space. He has a proven track record in transforming innovative ideas into ground-breaking products and services, fueling exponential growth, and reshaping the business landscape.

Eshwar is currently a founding partner at SAIGroup, where he identifies strategic investment opportunities and works with portfolio companies to spur innovation and growth.

Before SAIGroup, he held pivotal roles in several successful ventures. At Rubrik, he was instrumental in launching an innovative suite of IT infrastructure products, propelling the company to an annual run rate of $100M in just six quarters. As a founding executive at Rocket Fuel, his contributions were instrumental in the company’s meteoric rise from a start-up to earning over $400M in annual revenue and clinching the #1 spot on Deloitte’s Technology Fast 500™ list.

Earlier in his career, Eshwar founded Sensact Applications, focusing on IoT solutions, and iLeverage, which was acquired by Epiphany, where he later worked on its flagship CRM marketing and analytics platforms.

Eshwar serves as an advisor to emerging companies nurtured by Singularity University and Alchemist Accelerator. He’s also a charter member of TiE Silicon Valley. His academic accomplishments include a bachelor’s of technology degree from IIT Madras, a master’s degree in computer science and management of technology degree from U.C. Berkeley. He has authored several academic publications and holds six patents.

Sam Osman is a healthcare technology executive, board director, and former CEO with more than two decades of experience building and scaling data-driven healthcare and life sciences businesses. Throughout his career, he has helped pharmaceutical, care-delivery and manufacturing companies modernize clinical development and commercialization through the application of software and technology-enabled services. He has led multiple private equity-backed and public organizations through transformational growth, strategic acquisitions, and successful exits.

Most recently, Sam served as Chief Executive Officer of Endpoint Clinical and Neovance, two global pharmaceutical services businesses that he sold to private equity in 2024. Endpoint Clinical was one of the industry’s leading providers of real time technologies necessary for managing patient randomization, trial blinding, and drug supply optimization across thousands of global clinical trials. Neovance provides technology-enabled patient support, specialty pharmacy, reimbursement, and field services that improve access and adherence for therapies ranging from blockbuster oncology medicines to GLP-1s.

Prior, Sam served as President of Enabling Solutions at Fortrea, where he led a global $600 million technology and services business delivering clinical technology, data solutions, patient engagement and commercialization services to pharmaceutical and biotechnology companies worldwide. As a member of Fortrea’s executive leadership team, he played a key role in the company’s separation from Labcorp and successful IPO.

Earlier, Sam served as Chief Executive Officer of Science & Medicine Group, a leading provider of market intelligence, research, and analytics serving the life sciences ecosystem. The organization delivers data and strategic insights across laboratory diagnostics, precision medicine, molecular biology, instrumentation, and pharmaceutical markets.

Previously, Sam served as Chief Executive Officer of Cenduit, where he transformed the company from a focused point solution provider into a broader clinical technology platform supporting global trial operations. Under his leadership, the business expanded internationally, diversified its software portfolio, and increased enterprise value before its acquisition by a Fortune 500 healthcare organization.

Earlier in his career at Quintiles (now IQVIA), Sam helped shape many of the digital capabilities that have since become foundational across modern clinical research. He led the Connected Devices business, developing one of the industry’s earliest enterprise platforms for collecting and analyzing wearable, sensor, and medical device data in clinical trials. He also led the Digital Patient organization, advancing technologies that enabled remote participation and decentralized clinical studies years before virtual trials became mainstream.

In addition to his executive leadership experience, Sam has served on the boards of numerous healthcare technology and life sciences companies, including LabConnect, Cumulus Neuroscience, QuartzBio, DrugHunter, CREO, and others. Sam has advised and presented to the U.S. Food and Drug Administration on the application of connected devices, wearable technologies, sensors, and digital endpoints in clinical research. He has been recognized as one of PharmaVOICE’s Top 100 Leaders in Healthcare, named among the North Carolina Business Journal’s Top 40 Leaders, and recognized as one of Pennsylvania’s Top 25 Entrepreneurs.

Jason Williams is a principal for SAIGroup, focused on executing acquisitions across several verticals. Prior to joining SAIGroup in 2018, Jason worked as an investment professional at Golden Gate Capital and at The Gores Group, where he focused on investments in the industrial and technology sectors. Previously, he worked as a consultant in the Dallas office of the Boston Consulting Group, where he conducted numerous projects in the technology media and telecom industries.

Jason has a bachelor degree in neurobiology with a secondary degree in economics from Harvard College.

Nick Balay is the Principal of the SAIGroup investment team, responsible for sourcing, evaluating, and executing acquisitions across healthcare and other vertical sectors.

Prior to joining SAIGroup in 2022, Nick was a project leader in the Minneapolis office of the Boston Consulting Group, where he served healthcare, public sector, industrial goods, and private equity clients on various topics, including strategy, data & analytics, organization design, and buy-side due diligence. Previously, he worked in corporate development at Optum/UnitedHealth Group where he evaluated and executed M&A transactions in healthcare information technology, services, and delivery.

Nick earned his MBA with high honors from the University of Chicago Booth School of Business. He also holds a bachelor’s degree in economics from the University of Chicago with a minor in Near Eastern languages and civilizations.

Senjie is a senior associate on the SAIGroup investment team, responsible for evaluating and executing acquisitions. Prior to joining SAIGroup, Senjie was an investment banking analyst at Needham & Company, where he worked on M&A transactions in the software, internet, digital media, and consumer technology sectors. Previously, Senjie worked at Macquarie Capital as an investment banking analyst.

Senjie holds a bachelor’s degree in economics and statistics from the University of California, Berkeley.

Alec is a senior associate on the SAIGroup investment team, focused on evaluating and executing acquisitions. Prior to joining SAIGroup, Alec was an associate in Citigroup’s investment banking division where he worked on M&A, debt, and equity transactions in sectors including software, internet, consumer technology and property technology sectors. Previously, Alec worked in Citigroup’s debt capital markets group, advising on corporate financings in technology, media, and telecommunications markets.

Alec graduated summa cum laude with a bachelor’s degree in finance from the University of Connecticut, School of Business.

Alec can be reached at alec.pisanelli@saigroup.ai.

Justin Zhao is an investment associate on the SAIGroup investment team, where he is responsible for evaluating and executing acquisitions.

Before joining SAIGroup in 2025, he was an investment professional at HGGC, focused on the technology, consumer, and business and financial services sectors. Prior to that, he worked as an analyst in Wells Fargo Securities’ technology investment banking division.

Justin holds a degree in managerial economics from the University of California, Davis.

Stacey Pellizzari is a seasoned Executive Assistant supporting senior investment professionals at SAIGroup. With more than 15 years of experience, she has supported senior executives and teams across private equity, technology, healthcare, and investment organizations, including Electronic Arts, Stanford University’s Department of Emergency Medicine, KKR, Sapphire Ventures, The Carlyle Group, and Patient Square Capital.

With additional experience in human behavior and well-being, Stacey brings a distinctive perspective to executive support, combining operational excellence with sound judgment, adaptability, and a thoughtful, collaborative approach.

With more than 30 years of technology leadership and extensive experience in the automotive industry, Sanjay brings a deep understanding of AI and machine learning applications to SymphonyAI. He has a particular focus on developing solutions at the intersection of devices, sensors, cloud solutions, and data integration.

Before joining SymphonyAI, Sanjay served as president and CEO at Cerence, leading its 2019 spin-out from Nuance. Sanjay was responsible for day-to-day operations and financial performance at Cerence, which has more than 60 automotive customers that use its technology in more than 350 million vehicles globally.

Before Cerence, Sanjay served as president of the Connected Services Division and chief technology officer of Harman Industries International until 2019. Between 2010 and 2019, he served as president and chief executive officer of Symphony Teleca Corporation. Harman acquired Symphony Teleca in January 2015. Sanjay was responsible for the day-to-day operations of Symphony Teleca and its overall financial performance. Sanjay joined Symphony Teleca from Aricent, where he served as president and chief operating officer. Aricent is a KKR-owned privately held company with global operations in over 25 countries and more than 10,000 employees. At Aricent, he was responsible for the company’s strategy, sales, marketing, and the management and oversight of several high-growth business units and various functional units.

Before Aricent, Sanjay was the chairman, CEO, and co-founder of Inkra Networks, a company credited with defining the virtual networking market segment. Sanjay also held chief strategy, development, sales, and management roles at Netopia, StarNet, and Advanced Micro Devices (AMD). Sanjay has authored several networking-related publications and books and chaired the IEEE 802 and ANSI X3T9 standards sub-groups.

Sanjay holds a master’s degree in electrical engineering from Brunel University, England, and a bachelor of science degree in electronics and communications from REC Kurukshetra, India.

Eron Kelly is the Chief Executive Officer of ConcertAI, where he leads the company’s mission to transform life sciences and healthcare through enterprise-grade artificial intelligence, real-world data, and analytics solutions. Since joining ConcertAI in 2025, Kelly has focused on accelerating the company’s AI innovation agenda, advancing its product roadmap, and expanding value for life sciences and provider customers globally.

Prior to ConcertAI, Kelly served as President of Inovalon, a cloud-based healthcare SaaS and data analytics provider, where he drove the company’s transition into a pure-play cloud and AI-enabled business while delivering sustained double-digit growth.

With more than two decades of leadership experience in technology and cloud services, Kelly held senior roles at Amazon Web Services (AWS) and Microsoft. At AWS, he led worldwide product marketing for over 40 services across key categories, contributing to significant revenue expansion. At Microsoft, he played a central role in the creation and growth of Office 365 and led global product and sales organizations.

Kelly holds a Bachelor of Science in Electrical Engineering from Princeton University and an MBA from Harvard Business School

Deepthi Bathina is the Founder and CEO of GW RhythmX, an AI-native company defining the category of Enterprise Precision Care AI and building the large-scale foundation for the next generation of intelligent, connected Smart Hospitals. Formed through the merger of Get Well and RhythmX AI, the platform is deployed across more than 150 health systems, reaching over 85 million patients including 8 million U.S. military veterans and is powered by one of the industry’s deepest healthcare datasets spanning 300 million patient records and 4.4 billion annual claims. Prior to founding RhythmX AI, Bathina held senior executive roles across the health technology industry, including Chief Product Officer at Humana, and COO and global leadership roles at Nuance Communications and Wolters Kluwer Health. She has led global product, operations, and technology organizations at scale, managing multi-billion-dollar P&Ls and operating across 170+ countries.

Following treatment for non-Hodgkin’s lymphoma, Michael O’Neil emerged inspired to finish his graduate studies unexpectedly interrupted by cancer. Moving from concept to business plan, Michael launched Get Well in August 2000 to tackle an unaddressed problem in healthcare: empowering patients to take control of their healthcare journey. Michael’s vision for transforming the patient experience launched a healthcare technology segment called Interactive Patient Care. Two decades later, Get Well works with leading healthcare organizations and touches millions of patients and families around the world. Today, he leads the global digital health company as founder and CEO.

Michael also serves as executive chairman at PerfectServe, a private equity-backed clinical communications company, and as a limited partner of two early-stage venture capital firms focused on digital health. Michael is a past board member of the Leukemia & Lymphoma Society and the DAISY Foundation and serves on the board of the Washington, D.C., chapter of the Young Presidents Organization. Michael is a former Ernst & Young Entrepreneur of the Year Winner and, in 2019, was named an Aspen Institute Health Innovators Fellow. In 2021, he received The Global Good Fund’s Social Entrepreneur of the Year award and Georgetown Entrepreneurial Alliance’s Social Impact award. Today, Michael leads breakthrough work leveraging AI and community navigators to address maternal health equity and youth mental health among underserved communities.

Michael holds a Bachelor of Arts from the University of Notre Dame and a Juris Doctor and Master of Business Administration from Georgetown University.